Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

(marketscreener.com) Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma at the ASCO Gastrointestinal Cancers Symposium,...https://www.marketscreener.com/quote/stock/ZYMEWORKS-INC-34658200/news/Zanidatamab-Clinical-Data-Selected-For-Presentation-At-The-American-Society-Of-Clinical-Oncology-AS-42549506/?utm_medium=RSS&utm_content=20221214